Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients)

Eltohamy, Mahitab Ibrahim; Badawy, Omnia M.; kinaai, Naglaa El; Loay, Iman; Nassar, Hanan R.; Allam, Rasha Mahmoud; Sakr, Mohamed

doi:10.31557/apjcp.2018.19.12.3581

Cited by 13 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TOP2A can be used as a potential biomarker to predict the prognosis of patients with malignant tumors and screen out high-risk cases in order to enable individualized treatment ( 21 ). In a study on triple-negative breast cancer, a significant association was observed between the TOP2A gene and chromosome 17 polysomy (CEP17) status, and TOP2A has a certain predictive effect on the therapeutic effect of anthracycline drugs ( 22 ). Wittmann et al ( 23 ) confirmed that the high expression of TOP2A was associated with tumor metastasis and death outcome by analyzing 102 cases of nephroblastoma.…”

Section: Introductionmentioning

confidence: 99%

High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis

et al. 2020

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignant tumor in the clinic. Although there are increasing numbers of available treatment methods, their therapeutic effects are not satisfactory. The clinical indicators commonly used to predict the prognosis of HCC include tumor size, degree of cirrhosis, degree of tumor differentiation and tumor microvascular invasion; however, there are currently no molecular indicators that can predict the prognosis of HCC. Due to the differences in the progression of liver cancer among individuals, there is a growing need for prognostic biomarkers to accurately stratify patients for appropriate risk-adaptive treatment. The DNA topoisomerase 2-α (TOP2A) gene, which is located on human chromosome 17, encodes DNA topoisomerase IIα. Previous studies have demonstrated that TOP2A indicates a poor prognosis in patients with various types of tumors, but no such studies are currently available on HCC. By analyzing the differential expression of TOP2A in 50 pairs of tumor and paracancerous tissue samples in The Cancer Genome Atlas (TCGA) database, the present study revealed that the expression of TOP2A was significantly higher in tumor tissue compared with that in paracancerous tissue (P=6.319x10-16). In the collected clinical samples, the mRNA expression levels of TOP2A were significantly upregulated in HCC tumor tissues compared with those in the paracancerous tissues (P=6.40x10-3), suggesting that TOP2A was associated with the occurrence and development of liver cancer. In addition, the associations between TOP2A expression, clinicopathological features and prognosis were analyzed using a multi-center large sample dataset from TCGA database, and the results demonstrated that high expression of TOP2A was associated with a higher T stage, poorer clinical stage and higher histological grade compared with those in patients with low TOP2A expression. High expression of TOP2A was also identified to be associated with a poor prognosis of HCC, particularly in Asian populations. These results suggested that high expression of TOP2A in HCC tissues may be closely associated with tumor progression and metastasis, which may be used as a biological indicator to predict tumor prognosis in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 32 It has been reported that this topoisomerase could function as a target for anti-cancer therapy, and a variety of mutations in this gene are associated with the development of drug resistance. 33 - 35 Moreover, TOP2A is commonly amplified in thyroid cancer according to the COSMIC and cBioPortal databases, and the mutational frequency is approximately 1%. CDC20 encodes a protein that acts as a regulatory factor for multiple mitotic processes 36 ; this protein has been reported in various malignancies and plays a vital role in tumorigenesis and progression.…”

Section: Discussionmentioning

confidence: 99%

Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis

Zhu

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid cancer that results in fatal clinical outcomes; the pathogenesis of this life-threatening disease has yet to be fully elucidated. This study aims to identify the hub genes of ATC that may play key roles in ATC development and could serve as prognostic biomarkers or therapeutic targets. Two microarray datasets (GSE33630 and GSE53072) were obtained from the Gene Expression Omnibus database; these sets included 16 ATC and 49 normal thyroid samples. Differential expression analyses were performed for each dataset, and 420 genes were screened as common differentially expressed genes using the robust rank aggregation method. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were conducted to explore the potential bio-functions of these differentially expressed genes (DEGs). The terms and enriched pathways were primarily associated with cell cycle, cell adhesion, and cancer-related signaling pathways. Furthermore, a protein-protein interaction network of DEG expression products was constructed using Cytoscape. Based on the whole network, we identified 7 hub genes that included CDK1, TOP2A, CDC20, KIF11, CCNA2, NUSAP1, and KIF2C. The expression levels of these hub genes were validated using quantitative polymerase chain reaction analyses of clinical specimens. In conclusion, the present study identified several key genes that are involved in ATC development and provides novel insights into the understanding of the molecular mechanisms of ATC development.

show abstract

“…showed that TOP2A played a predictive role for anthracycline-based chemotherapy [37]. CCNB1, known as cyclin B1, is a highly conserved cyclin.…”

Section: Discussionmentioning

confidence: 99%

Identification of Potential Target Genes in HER-2 Positive Breast Cancer by Bioinformatics Analysis.

Song

Quan

Lyu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: HER-2 positive breast cancer has a high risk of for relapse, metastasis and drug resistance, and is correlated with a poor prognosis. Thus, the study objective was to reveal target genes and key pathways in HER-2 subtype breast cancer. Methods: The gene expression dataset (GSE29431) was downloaded from the Gene Expression Omnibus database(GEO), and the differentially expressed genes (DEGs) were determined using LIMMA package in R software. Subsequently, Functional enrichment analysis were performed in ClusterProfiler package of R platform. The Search Tool for the Retrieval of Interacting Genes (STRING) database was used to construct a Protein-Protein Interaction (PPI) network of DEGs. Module analysis and target genes were identified by Cytoscape software. Further more, The influence of target genes on overall survival (OS) was assessed using the Kaplan-Meier plotter database.Results: The differential expression analysis revealed 96 genes were up-regulated while 407 genes were down-regulated in HER-2 positive breast cancer tissue compared to normal breast tissue. Functional enrichment analysis showed that the DEGs were mainly involved in regulation of lipid metabolic process, PPAR signaling pathway and PI3K-Akt signaling pathway. PPI network construction revealed a total of 199 nodes and 560 edges, and 12 target genes were identified by the highest value of degree. In addition, target genes were associated with worse overall prognosis, including NUSAP1, PTTG1, CEP55, TOP2A, CCNB1, CENPF, MELK, AURKA, UBE2C, BUB1B, KIF20A and RRM2.Conclusion: The present study identified 12 target genes associated with the development of HER-2 subtype breast cancer, which may help to provide new biomarkers and therapeutic targets.

show abstract

Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients)

Cited by 13 publications

References 40 publications

High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis

High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis

Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis

Identification of Potential Target Genes in HER-2 Positive Breast Cancer by Bioinformatics Analysis.

Contact Info

Product

Resources

About